Contribute Try STAT+ Today

The discovery of a rare genetic mutation that seems to protect certain people from becoming obese may one day lead to drugs that can help people lose weight or prevent other complications like diabetes and heart disease, said Regeneron Pharmaceuticals co-founder and Chief Scientific Officer George Yancopoulos. Regeneron scientists and other collaborators published new findings about this protective mutation in the journal Science.

Yancopoulos sat down with the hosts of “The Readout LOUD” to discuss Regeneron’s genetic research efforts, which include partnering with Intellia Therapeutics on the first in vivo CRISPR treatment for a rare nerve disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment